Anti-EGFR/Anti-4-1BB Bispecific Antibody HLX35 clinical trials
Also written HLX35.
How each study uses Anti-EGFR/Anti-4-1BB Bispecific Antibody HLX35 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-EGFR/Anti-4-1BB Bispecific Antibody HLX35 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Shanghai Henlius Biotech (2) · Binacea Pharma, Inc. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses Anti-EGFR/Anti-4-1BB Bispecific Antibody HLX35 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Safety and Preliminary Efficacy of BNA035 in Patients With Advanced Solid TumorsRecruitingPhase 1Binacea Pharma, Inc.NCT05150457Written as BNA035How we know
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid TumorsNot yet recruitingPhase 1Shanghai Henlius BiotechNCT05442996Written as HLX35How we know
- HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1Shanghai Henlius BiotechNCT05360381Written as HLX35How we know